MedTrace Logo

Evaluation of Kaletra Therapy Over the Long-term

NCT01083810 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 284

Last updated 2011-08-11

Study results available
· View outcomes & findings →

Summary

Long term observation of patients under lopinavir/ritonavir containing therapy

Conditions

  • Human Immunodeficiency Virus

Interventions

DRUG

Lopinavir/Ritonavir (Kaletra)

3 capsules 2xdaily or 2 tablets 2xdaily Kaletra

Sponsors & Collaborators

Principal Investigators

  • Stefan Simianer, MD · Abbott Germany, Medical Department

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-06-30
Primary Completion
2010-06-30
Completion
2010-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01083810 on ClinicalTrials.gov